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The abuse of heroin (diamorphine) and heroin deaths are growing around the world. The 
interpretation of the toxicological results from suspected heroin deaths is notoriously difficult 
especially in cases where there may be limited samples. In order to help forensic practitioners 
with heroin interpretation we determined the concentration of morphine (M), morphine-3-
glucuronide (M3G) and morphine-6-glucuronide (M6G) in blood (femoral and cardiac), brain 
(thalamus), liver (deep right lobe), bone marrow (sternum), skeletal muscle (psoas) and 
vitreous humor in 44 heroin related deaths. The presence of 6-monoacetylmorphine (6-
MAM) in any of the postmortem samples was used as confirmation of heroin use. 
Quantitation was carried out using a validated LC-MS/MS method with solid phase 
extraction. We also determined the presence of papaverine, noscapine and codeine in the 
samples, substances often found in illicit heroin and that may help determine illicit heroin 
use. The results of this study show that vitreous is the best sample to detect 6-MAM (100% of 
cases), and thus heroin use. The results of the M, M3G and M6G quantitation in this study 
allow a degree of interpretation when samples are limited. However in some cases it may not 
be possible to determine heroin/morphine use as in 4 cases in muscle (3 cases in bone 
marrow) no morphine, morphine-3-glucuronide or morphine-6-glucuronide was detected, 
even though they were detected in other case samples. As always postmortem cases of 
suspected morphine/heroin intoxication should be interpreted with care and with as much 
case knowledge as possible.  
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1. Introduction 
Heroin (diacetylmorphine or diamorphine (BAN)) is an opioid analgesic that is abused by 
around 16.5 million people worldwide and in 2015 was responsible for an estimated 150,000 
deaths 
1
. The use of heroin is however changing around the world. Europe is currently seeing 
a recent increase in deaths after seeing a long term decline in the use of heroin 
2
, this increase 
in abuse is also being seen in other parts of the world such as South West and Central Asia 
1
. 
North America in particular has seen a large 145% increase in heroin users since 2007 
1
. 
Although there has been a recent increase in the use and abuse of synthetic opioids 
worldwide 
2
 the abuse of heroin is still a global problem to be addressed. Heroin is commonly 
abused by various routes the most common ones being intravenously, orally and inhalation 
(smoking) 
3
. Heroin, once absorbed, is rapidly deacetylated and pharmacologically activated 
by metabolism with the formation of 6-monoacetylmorphine (6-MAM) with a half-life of 
about 2-5 minutes 
4
.  6-MAM is then hydrolysed rapidly to morphine (t½ ~15 min). The 
major final steps of the metabolism of morphine are the conjugation of morphine to form the 
pharmacologically inactive morphine-3-glucuronide (M3G) and the pharmacologically active 
morphine-6-glucuronide (M6G). N-demethylation of morphine also results in the formation 
of the inactive minor metabolite normorphine 
5
. Due to various factors it is difficult to 
interpret postmortem morphine concentrations. These factors include overlapping 
concentrations of morphine measured in deceased and living patients
6
, the rapid development 
of tolerance to opiates in users 
6
 and the possibility of changes in the blood concentration of 
opiates after death 
7
. Due to the routine introduction of LC-MS/MS into laboratories it is 
becoming more common to quantitate the concentrations of morphine, morphine-3-
glucuronide and morphine-6-glucuronide in post mortem samples 
8, 9
 rather than to determine 
the concentration of free morphine and total morphine levels (free + conjugated morphine 
levels) to determine possible toxicity 
10
. To fulfill the lack of information and help colleagues 
in data interpretation we report the concentration of morphine, morphine-3-glucuronide and 
morphine-6-glucuronide whilst also showing qualitative results for noscapine, papaverine and 
codeine in 44 cases in a series of commonly sampled postmortem matrices (femoral blood, 
cardiac blood, brain (thalamus), liver (deep right lobe), bone marrow (sternum), muscle 
(psoas) and (vitreous) using a validated LC-MS/MS method.  
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2. Material and Methods 
 
2.1 Sample collection 
 
All samples were collected and analysed as part of the routine autopsy procedure for 
suspected heroin deaths (2010-2012). These samples included femoral venous blood 
(unpreserved sample and preserved sample with potassium fluoride/sodium oxalate), 
unpreserved cardiac blood, muscle (psoas), bone marrow (sternum), liver, brain (thalamus) 
and preserved vitreous humour. Sample collection was performed according to the following 
protocol:  
 
All fluid samples (blood, vitreous) were collected using a 12 gauge needle and syringe. 
Unpreserved fluid samples were stored in a 20 ml Sterlin® tube. Preserved samples were 
stored in a 2.5% w/v sodium fluoride/potassium oxalate tube. Femoral venous blood was 
collected by the superior clamping of the femoral vein before sampling. Cardiac blood was 
sampled for either of the ventricles. Vitreous humour was sampled from both eyes and mixed. 
For all tissue samples the area was wiped clean before sampling commenced, samples were 
stored in 20 ml Sterlin® tubes. For psoas muscle sampling an incision was then made 
anteriorly to remove approximately 1cm
3
 of interior tissue to minimise external 
contamination. For liver an incision was made across the middle right lobe to provide a 1cm
3
 
of centrally located tissue to avoid external contamination. For bone marrow the sternum was 
cut laterally between the 1
st
 and 2
nd
 rib to allow access to the bone marrow.  Tweezers were 
used to collect between 0.5 - 1 g of bone marrow from the sternum cavity. For the brain 
approximately 1 cm
3 
of the thalamus was wiped clean then collected. Samples were stored at 
4ºC for 1 week and then stored at -20 ºC until analysis. All analysis was completed with 5 
weeks of the samples being collected.  
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2.3 Standard Solutions, Calibration Curve and Quality Control  
  
Morphine (1mg/ml), morphine-3β-D-glucuronide (M3G) (1mg/ml) and morphine-6-β-D-
glucuronide (M6G) (100µg/ml) methanolic standards (LGC Standards, Teddington UK) were 
used to prepare a fresh 25 mg/L combined standard solution then diluted with blank equine 
plasma (TCS Biosciences, Buckingham, UK) to prepare a 7 point calibration curve (0.01, 
0.025, 0.05, 0.1, 0.25, 0.5 and 1 mg/L). Separate quality control (QC) standards were 
prepared in blank equine plasma at a concentration of 0.025 and 0.5 mg/L. Morphine-3β-D-
glucuronide-D3 (M3Gd3) and morphine-D3 (Md3) both 1 mg/ml methanolic solutions (LGC 
Standards, Teddington UK) were diluted in water at the final concentration of 1mg/L and 
used as Internal Standards. HPLC grade acetonitrile, ammonium carbonate, ammonium 
formate, formic acid and HPLC grade methanol were supplied by Fisher Scientific 
(Loughborough UK).   
 
2.3 Sample Preparation and extraction 
 
2.3.1 Tissue Sample Preparation 
For extraction, liver, brain, bone marrow and muscle were homogenised, adapting and 
applying a previous published procedure
11
. In summary tissues were dried using tissue paper, 
accurately weighted and homogenised (Janke & Kunkel Ultra-Turrax T25) with 4 parts of 
water. Thalamus and bone marrow were accurately weighted and homogenised with 2 parts 
of methanol and 6 parts of hexane. The methanol/hexane homogenates were then centrifuged 
and the top hexane layer discarded.  
 
2.3.2 Sample Extraction 
The sample extraction was based on a previously published method
10
. Following 
homogenisation 200 µl of liver was diluted with 1000 µl equine plasma. For all the other 
biological samples, quality controls and calibrators, 150 µl of sample was diluted with 150 µl 
equine plasma.  900 µl of liver sample and 300 µl of all the other biological samples were 
spiked with 50 µl of Md3 and 50 l of M3Gd3 (IS). After vortexing, 1ml of 0.5M 
Ammonium Carbonate solution was added to each sample, now ready to be extracted. Solid 
phase extraction was performed using a Varian Bond Elut LRC-C18, 200mg cartridges. The 
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cartridges were conditioned using 2ml of methanol followed by 2ml of water and finally 1ml 
of 0.5M ammonium carbonate solution. Then, 1ml of the sample was loaded onto the 
cartridge and allowed to drain to the clear tube. The cartridges were washed using 5ml of 
0.005M ammonium carbonate solution the washing solution discarded and the cartridges 
dried for 5 minutes. 1ml of 70:30 ACN:H2O solution was loaded onto the cartridges and 
allowed to elute into a clean glass vial. The eluents were evaporated to dryness under air at 
45°C. The evaporated eluent was reconstituted with 100 µl of freshly made LC-MS mobile 
phase (96% phase A: 4% phase B), transferred into a HPLC vial for analysis. 
 
2.4 Sample Analysis  
A 1200 Agilent HPLC system interfaced with an Applied Biosystem 3200 Q TRAP triple-
quadrupole linear ion trap mass spectrometer (AB Applied Biosystem, Foster City,  CA, 
USA) equipped with an electrospray ionization source (ESI) was used to analyse all the 
samples. Data acquisition was achieved with Analyst 1.5 software.  Separation of all analytes 
was accomplished using a Phenomenex Synergi 4µ Polar-RP 80A Column (150 mm × 2 mm 
× 4µm) protected by a Phenomenex Security Guard column (Macclesfield, UK). Mobile 
Phase A consisted of a 1mM ammonium formate and 0.1% formic acid solution (around pH 
2.7). Mobile Phase B was a 50% acetonitrile solution with 1mM ammonium formate and 
0.1% formic acid (around pH 3.8).   
The qualitative and quantitative screening were based on a previously published method 
10
. 
For the qualitative screening a gradient method was applied. Following injection the eluent 
was at 1.5% ACN (97% A, 3%B) for the first 3 min, ramping to 47.5% ACN over 5 min (5% 
A, 95%B) and held for 3.5 min. The eluent was then reduced back to the initial 1.5% ACN 
over 0.5 minutes and was held for a further 3 minutes. This gave a total run time of 15 
minutes. Flow rate was 0.6 ml/min, injection time was 20 seconds and column temperature 
was set at 40 °C. The injection volume was 20l. The following ion transitions and retention 
times were observed: Morphine (m/z 286/286, 286/201, 286/165), morphine-3-glucuronide 
(m/z 462/462, 486/286, 462/268), morphine-6-glucuronide (m/z 462/462, 486/286, 462/268), 
6-monoacetylmorphine (6-MAM) (m/z 328/328, 328/193, 328/165), noscapine (m/z 414/414, 
414/220), papaverine (m/z 340/340, 340/202), codeine (m/z 300/300, 300/215, 300/165). 
Internal standards: Morphine-d3 (m/z 289/289, 289/201, 289/165), morphine-3-glucuronide-
d3 (m/z 465/465, 485/289, 465/204).  
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Free morphine, M3G and M6G quantitation was achieved with an isocratic method of 1.5% 
acetonitrile (97% A, 3%B). The triple-quadrupole linear ion trap mass spectrometer 
performed the scan in positive mode using ion spray ionization (voltage 5500 V). The ion 
source temperature was set at 700 °C, DP 20 V, EP 10 V.  
 
2.5 Method Validation 
 
The method was validated according to the guidelines of Peters et al. 
12
, with the matrix 
effects being evaluated by the methods of Matuszewski et al. 
13
. The morphine, morphine-3-
glucuronide and morphine-6-glucuronide linearity (r
2
 >0.99) was achieved applying a linear 
regression with a 1/x weighting factor on a seven points calibration curve (0.01 mg/L, 0.025 
mg/L, 0.05 mg/L, 0.1 mg/L, 0.25 mg/L, 0.5 mg/L and 1 mg/L). A series of quality control 
samples in plasma at concentration of 0.025 mg/L and 0.5 mg/L for morphine and morphine 
glucuronides were prepared and analysed on different days to determine the precision (CV%) 
and accuracy (bias) of the method. Accuracy and bias (both interday (n=5) and intraday 
(n=30) were within the acceptable ranges (±15%) proposed by Peters et al. 
12
. The MRM 
transitions selected for quantitation were the following: for morphine 286/165 (against 
Morphine-d3 289/152), for Mophine-3-and-6-glucuronide 462/286 (both against Morphine-3-
glucuronide-d3 465/289). Lower limit of quantification and (LLOQ) and limit of detection 
(LOD) were determined as the minimum concentration that would produce a signal-to-noise 
ratio of ten and three respectively. The LOD for morphine, morphine-3-glucuronide and 
morphine-6-glucuronide were 0.004 mg/L, 0.003 mg/L and 0.004 mg/L respectively, with the 
LLOQ being 0.01 mg/L for all compounds. Evaluation of the results obtained for morphine, 
morphine-3-glucuronide and morphine-6-glucuronide in all biological matrices analysed 
indicated that it was possible to use the calibration curve in plasma for quantitation since all 
spiked tissue concentrations were all within 20% of the expected concentration.  
 
To investigate matrix effects; morphine, morphine-3-glucuronide and morphine-6-
glucuronide were spiked (along with IS) at different concentrations (0.025 mg/L and 0.5 
mg/L) in at least 5 different samples of SAGM blood (Transfusion Unit. Ninewells Hospital, 
Dundee, UK), porcine vitreous, homogenised porcine/bovine bone marrow, bovine  muscle, 
porcine brain and porcine/bovine liver (all local butcher); extracted, analysed and measured 
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against the plasma calibration curve to determine the deviation from the true value.  
Evaluation of the results obtained for morphine, morphine-3-glucuronide and morphine-6-
glucuronide in all biological matrices analysed indicated that it was possible to use the 
calibration curve in plasma for quantitation since all spiked tissue concentrations were all 
within 20% of the expected concentration. The concentrations of the solid matrices were 
calculated according to the method of Flanagan et al. 
11
. The validation results are shown in 
table 1. 
 
 
2.6 Statistical Analysis 
 
Morphine results obtained from all biological matrices underwent statistical Pearson 
Correlation analysis to determine whether any linear relation exist between different samples. 
The data was also analysed using “Principal Component Analysis” (PCA).  
PCA is an unsupervised multivariate procedure and is a well-known linear data compression 
and feature extraction technique 
14
. It derives new, uncorrelated variables that are linear 
combinations of the original variable set ordered by reducing variability. PCA is mainly used 
to reduce the dimensionality of a data set while retaining as much information as possible by 
eliminating the lowest-ranking variables. It is a simple and fast method but remains a linear 
approach, so any nonlinear correlation between variables will not be retained. The scores 
produced may be plotted in two or three dimensions to inspect the data. Therefore it might be 
possible to relate the data using statistical methods such as principal component analysis 
(PCA). 
 
3. Results and Discussion 
 
A total of 44 cases of death from heroin use were investigated. The presence of 6-
monoacetylmorphine (6-MAM) in at least one of the case samples and the case circumstances 
were used as confirmation of illicit rather than medicinal heroin use. Each sample collected at 
autopsy (cardiac blood, femoral blood, preserved (fluoride/oxalate) femoral blood, preserved 
vitreous, liver, bone marrow, psoas muscle and brain) underwent initial qualitative screening 
for morphine, morphine-3-glucuronide, morphine-6-glucuronide, codeine, 6-MAM, 
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papaverine and noscapine). Following the quantitative screen the levels of free morphine, 
morphine-3-glucuronide and morphine-6-glucuronide were determined in all samples.   
 
3.3 Age and gender of heroin users 
 
Of the 44 cases of death following heroin use 79.5% were male with a mean age of 36 years; 
(median 35 years; range 21 to 65 years). 20.5% were female with a mean age of 34 years, 
(median 33 years; range 21 to 46 years). The mean and median age for all cases (regardless of 
sex) was 35 years. Averages for age and gender were similar to previous other studies of 
heroin related fatalities 
6, 15
 
 
3.1 Qualitative Screening 
In the case of decomposition the full range of toxicological samples may not be available for 
testing. In order to determine the samples in which morphine, morphine-3-glucuronide and 
morphine-6-glucuronide can be detected we carried out qualitative screening of blood 
(femoral and cardiac), vitreous, liver, brain (thalamus), muscle (psoas) and bone marrow.  
The results of the qualitative screening are found in Table 2. The presence of morphine was 
confirmed in all cases for cardiac blood, unpreserved femoral blood, preserved femoral blood 
and vitreous with high levels of detection of morphine and in brain, liver, bone marrow and 
muscle samples (98%, 95%, 91% and 86% detection) respectively. Similar to the study by 
Thaulow et al 
16
, morphine-3-glucuronide was detected in all case samples for cardiac blood 
and unpreserved femoral blood. High levels of detection were observed in all other matrices; 
preserved femoral blood (98%), brain (84%), liver (98%) bone marrow (75%) samples, 
vitreous (95%) and muscle (84%) samples. Previous work 
16
 has only determined detection of 
M3G in vitreous (88%) and muscle (89%) which are similar to our data.  Thaulow et al. 
16
 in 
agreement with our data detected morphine-6-glucuronide in fewer matrices than morphine 
and morphine-3-glucuronide, in our data M6G exhibited with high rates of detection >86% in 
all samples apart from muscle (50%) bone marrow (41%) and thalamus (43%). This would be 
expected as more M3G is produced by metabolism of morphine than M6G 
17
. However we 
detected M6G in psoas in a higher number of cases (50% vs 9%) and also in vitreous humour 
(84% vs 44%) than the Thaulow et al. study 
16
.  These results suggest that the best matrices 
for the confirmation of free morphine and its glucuronide metabolites are blood (femoral and 
cardiac) > liver > vitreous. In muscle, bone marrow and brain, morphine will be detected in 
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most cases but not all of the time. This may mean that in decomposed bodies the use of 
morphine may not be able to be confirmed even if the deceased had taken morphine. The 
presence of morphine and its main metabolites morphine-3-glucuronide and morphine-6-
glucuronide have previously been reported in a number of human cases for various matrices 
and give similar results to those that we found in this study with morphine-3-glucuronide and 
morphine-6-glucuronide detectable in blood, vitreous, brain, liver, lung and kidney 
18-24
.  
 
The presence of morphine alone does not confirm the use of heroin as morphine can be 
produced as a metabolite of codeine and morphine can be abused by itself. In order to 
definitively identify the use of heroin, 6-MAM needs to be detected. However 6-MAM is 
unstable in the body being metabolised even after death by cholinesterases. With particularly 
high concentrations of esterases found in liver, heart, lung, kidney and blood 
25
. Our study 
shows that as with other studies 
24, 26, 27
 vitreous is the best sample for the detection of 6-
MAM being detected in 100 % of cases. In blood the 6-MAM was most stable in 
fluoride/oxalate preserved samples where it was detected in 61% of samples. In all other 
matrices 6-MAM was detected in <52% of case the worst samples for the detection of 6-
MAM was liver and bone marrow (2% and 5% respectively). However it is unclear why so 
little 6-MAM was detected in bone marrow as in previous human and animal studies 6-MAM 
has been shown to be detectable 2 months after death 
23, 28
. This may be due to the different 
sampling sites used between this study (sternum) and the previous studies (both femur) or a 
lack of time for 6-MAM to equilibrate with the bone marrow compartments before death 
occurred.  
 
Another important piece of information that can be obtained from toxicological screening is 
the determination of the use of heroin which can come from either illicit or medicinal 
(diamorphine) sources. The illicit heroin contaminants which occur in the largest amounts 
due to the processing of the opium poppy are noscapine, papaverine, codeine, 6-
acetylcodeine, thebaine, and narceine 
29
. The most commonly used biomarkers for illicit 
heroin are noscapine and papaverine as they are found in the opium poppy and have been 
found to survive the common two methods of heroin production, the lime method (South East 
Asia) and the ammonia method (West Asia) 
30
. The amount of noscapine and papaverine has 
been found to vary based on the batches of heroin. In 513 illicit seizures of heroin from the 
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Netherlands between 1994-1999 noscapine was detected in 15% and papaverine detected in 
1.3% (median values) 
29
. In 85 Iranian heroin samples (2008-2009) Akhgari et al 
31
 reported 
that 43.5% of samples contained noscapine and 42.4% papaverine. From another study 
carried out by O’Neil et al 32 only 5% of samples of Southeast Asian Origin contained 
papaverine and noscapine, where none of the illicit heroin of Indian origin had either 
papaverine or noscapine.  
It was also reported that 59% of illicit heroin of Pakistani origin contained noscapine and 
papaverine, whereas 88.4 % and 88.1 % of Iranian and Turkish origin respectively contained 
noscapine and papaverine. Illicit heroin samples have also been found not to contain 
noscapine and papaverine 
29-32
 so with these studies showing that varying concentrations of 
noscapine and papaverine can be found in illicit heroin samples and as both noscapine and 
papaverine can be found in over the counter drugs and foods containing poppy seeds. The 
centrally acting cough suppressant noscapine is commonly prescribed in Asia and several 
European countries and papaverine is available for the treatment of erectile dysfunction and 
as an analgesic as a component of papaveretum which contains morphine, papaverine and 
codeine 
33
. Several studies show that noscapine and papaverine are not present in illicit heroin 
samples and therefore negative results do not infer that illicit heroin was used. Use of illicit 
heroin attributed due to the presence of noscapine and papaverine should be done after 
excluding their provenance from other prescribed drugs and from patients that were given 
atracurium. 
 
Overall for all compounds investigated we found a slightly higher percentage of positive 
cases for preserved matrices (blood and vitreous) showing that more information can be 
gained from preserved blood samples compared to unpreserved blood samples. 
 
3.2 Quantitative results: 
 
Interpretation of the postmortem results requires investigation (case history), pathology and 
also laboratory analysis that are evaluated in the context of each other 
34
. In order for 
laboratory investigations to be placed into correct context data must be obtained from case 
studies of heroin death. To the best of the authors’ knowledge this is the first publication that 
has complete case studies for heroin deaths in a variety of matrices with both free morphine 
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and its glucuronides. We determined the concentrations of free morphine, morphine-3-
glucuronide and morphine-6-glucuronide in a variety of matrices as shown in Table 3. An 
overall summary of the results are given in table 4. The general consensus is that ‘gold 
standard’ sample for interpretation in postmortem toxicology is that of femoral blood which 
is thought to be affected the least by the “toxicological nightmare” of postmortem drug 
redistribution 
7
.  The free morphine levels in unpreserved femoral blood (median 0.21 mg/L, 
range 0.01-1.35mg/L, n=44) were not found to be significantly higher than that found in 
preserved femoral blood (median 0.14 mg/ L, range 0.01-1.19 mg/L, n=44). As can be seen in 
table 5 the mean values of free morphine are similar to a variety of other studies that reported 
free morphine levels in femoral blood. These results overlap with the free morphine blood 
levels reported in apprehended drivers in Sweden median 0.15 mg/L range 0.02-1.13mg/L. 
n=124 
6
 and so confirm other reports that the confirmation of death due to morphine must be 
confirmed from as much case information as possible rather than looking at drug reference 
ranges 
35
.  The morphine results that have typically been used in the past to determine the role 
of morphine in opiate deaths has been that of free morphine (unmetabolised morphine) and 
total morphine (unmetabolised morphine and metabolised morphine). However this does not 
allow investigation of the individual roles of the glucuronide metabolites in opiate toxicity. 
Due to the lack of previous studies, especially in non-blood matrices studies we also 
investigated the levels of morphine-3-glucuronide and morphine-6-glucuronide. The results 
are shown in table 2 and 3 as shown in table 5 these results are similar to the ranges that have 
been reported in previous studies that measured femoral blood. It has been suggested that the 
molar ratio of M3G:M6G might be responsible for the analgesic effect (and thus toxic effects 
of morphine) 
36
 however this is based on the assumption that M3G antagonises the analgesic 
(and also respiratory depressant) effects of M and M6G. This effect has been demonstrated in 
vivo following intracerebroventricular injections 
37, 38
 but has not been repeated in either 
animal studies 
39, 40
 or human studies in the more physiologically relevant intravenous 
injection 
41
. So the M3G:M6G ratio is unlikely to indicate the effects of morphine as 
previously suggested. Its relevance has also been called into question as we would have to 
assume that no detectable levels of both M3G and M6G were present before the 
administration of heroin, something that may not be true in chronic heroin/morphine users. It 
has also been found that the metabolites are not produced in equal amounts and that the 
amounts of glucuronide metabolites can depend on the route of administration 
17
.  
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Morphine-6-glucuronide has been shown in numerous studies to have a similar or greater 
analgesic potency than morphine 
41-43
, like morphine it is also thought to give a similar level 
of reward as morphine 
44-46
 but appears to have less of a respiratory depressant effect than 
morphine in human studies 
47
 possibly due having less affinity for the 2 opiate receptor than 
morphine. The 2 opiate receptor is thought to be responsible for the side effects of opiate 
drugs. Both morphine and M6G have similar affinities for the 1 receptor 48, 49.  
 
In all cases the concentrations of free morphine, morphine-3-glucuronide and morphine-6-
glucuronide were higher in cardiac blood than femoral blood. This was as expected as in 
previous studies that investigated both cardiac and femoral blood the cardiac blood was 
generally found to be higher than the femoral blood 
50-52
. Two studies have shown 
concentrations of free morphine that have been higher in femoral blood than cardiac blood. In 
one case the cardiac morphine concentration was 0.8mg/L (left ventricle), 0.46mg/L (right 
ventricle) with a femoral blood of 1.35mg/L 
20
. In a study performed on 4 cases of heroin 
related deaths Skopp analysed the concentration of morphine, M3G and M6G sampling the 
blood from different sites: aorta, infra- and suprarenal potion of inferior vena cava, the 
superior vena cava, the femoral and subclavian vein, right and left ventricles 
53
. Case number 
one showed concentration of cardiac blood (left and right ventricle) for all three compounds 
higher than the one in femoral blood (left and right femoral vein). For the second case 
morphine concentration in the blood from the right ventricle was lower than the blood in the 
right femoral vein. In the same case M6G was overall higher in cardiac blood than femoral 
blood. M3G was not quantifiable in cardiac blood due to biological matrix interferences. The 
third case morphine in left femoral blood was lower than the left ventricle but higher than the 
right ventricle, and also M6G presented a higher concentration in the blood from the left 
femoral vein than the blood of the left ventricle. Case four had a lower concentration for 
M3G and M6G in the blood from the left ventricle than the right and left femoral vein.  
 
Liver was historically a common tissue for toxicological analysis due to its large mass. We 
also investigated the free morphine & morphine glucuronide metabolites in the right lobe of 
the liver a part of the liver that is thought to be the least effected by postmortem 
redistribution, especially from the stomach 
7
. Concentrations of free morphine in liver 
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showed a mean concentration of 0.62mg/kg with a range of 0-2.55mg/kg, M3G was 
0.7mg/kg (range 0-4.68), M6G was 0.29mg/kg (range 0-1.76). We are the first study to show 
free morphine and the glucuronide metabolites of morphine in liver samples. Only Klingman 
reported in study of one case (intoxication following morphine, tramadol and atracurium 
intake) the concentration of morphine as well M3G and M6G in liver which were 2.32, 14.94 
and 15.1 mg/kg respectively 
55
.  Three other studies investigated free morphine 
concentrations alone. Wyman analysed 25 heroin deaths. Morphine concentration in liver 
averaged 0.04-1.56 mg/kg (mean 0.33 mg/g) so slightly lower than our results 
18
. Moriya 
described just one case with a morphine concentration of 1.44 mg/kg 
20
. Felby investigated 
morphine concentration in the liver of 14 heroin deaths. The range reported was 0.4-18 
mg/kg, average 2.57mg/kg 
21
.  In our study liver was the biological matrix showing the 
highest mean concentration of morphine (0.62 mg/kg). In the other studies investigating liver 
they also found liver to contain the highest concentration of morphine of all the matrices 
tested 
18, 20, 21, 54
. The high concentrations of morphine and metabolites in the liver may mean 
that the liver is a possible depot for postmortem redistribution.  
 
Muscle is commonly used for detection of morphine use rather than for interpretive purposes 
55
. However it has been suggested that muscle may give a reasonable estimate of the 
concentration of a drug in the body at the time of death 
56
. We quantitated free morphine, 
M3G and M6G in the psoas muscle. Results given as mean and range. Morphine 0.19mg/kg, 
0-1.13mg/kg; M3G 0.09mg/kg, 0-0.91mg/kg; M6G 0.03mg/kg, 0-0.15mg/kg. As with the 
studies in the liver previous studies have only investigated free morphine concentrations in 
the muscle and didn’t investigate M3G and M6G. The other studies, muscle was either from a 
different site (thigh) or was not given which as drug concentrations have been shown to differ 
in the muscle depending on the site of sampling 
57
 the results may not be directly comparable 
to the current study. With Moriya, 1 case of heroin death was considered. Right femoral 
muscle had a morphine concentration of 0.74 mg/kg 
20
. Felby reported the results of 
morphine concentration analysed in 14 cases of victims due to heroin intake 
21
. Muscle 
morphine concentration averaged 0.39 mg/kg (range 0-2 mg/kg). Morphine concentration in 
muscle was 1.13 mg/kg in Klingmann study 
54
. All of these study demonstrated larger 
concentrations of morphine compared to the data presented here.  
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Bone marrow has been suggested as a possible source of information about morphine in 
decomposed bodies due to bone marrow being protected from the environment in 
decomposition situations 
23
. We found that the mean concentration of free morphine in bone 
marrow was 0.25 mg/kg range 0-3.23 mg/kg. This was similar to the bone marrow morphine 
level found in a heroin addict immediately after death (0.2 mg/kg). It is unclear if the 
concentrations of morphine vary depending on the bone marrow sampling site.  
 
The brain is an important site of action for the respiratory depressant effects of morphine, the 
effect that is thought to cause death in heroin fatalities 
58
. We investigated the concentration 
of free morphine in the thalamus. The mean concentration of free morphine was 0.26 mg/kg 
(range 0-1.96 mg/kg); M3G 0.06mg/kg, 0-1.12 mg/kg; M6G 0.01 mg/kg. Previous studies 
have looked at the concentrations of morphine in the brain, but as with other tissues there is 
no standard sampling site. One study looked at two regions in the brain medulla (mean 0.24 
mg/kg range 0.05-0.45mg/kg) and cerebellum (mean 0.34 mg/kg, range 0.05-0.67mg/kg) 
59
. 
These results were similar to those that we obtained but may indicate that the concentration 
of morphine is not uniform thorough out the brain and for future comparison of cases specific 
sampling sites should be identified. Other cases where the brain was analysed also gave 
similar concentrations as found in our study. Moriya 
20
 presented the results of a subject who 
died after injecting heroin and methamphetamine. Cerebrum was analysed morphine 
concentration was 0.34 mg/kg. In another study 
22
 Pare analysed morphine concentration in 
the thalamus 0.24 mg/kg (range 0-0.67 mg/kg). Only one study investigated the concentration 
of morphine as well as its metabolites in and unidentified area the brain. Klingmann found 
the concentration of morphine was 0.52 mg/kg, M3G 1.42 mg/kg and M6G 1.24 mg/kg 
54
. 
As discussed above vitreous is commonly used to confirm the use of heroin, via the detection 
of 6-MAM when morphine is detected due to the stability of 6-MAM in vitreous but is not 
commonly used for the quantitation of morphine levels. The median concentration of 
morphine, M3G and M6G in this study for vitreous were 0.08mg/L (range 0.01-0.49 mg/L); 
0.10 mg/L (range 0.01-0.65 mg/L) and 0.02 mg/L (0.01-0.19 mg/L) respectively. The 
morphine concentration here reported was the lowest among all the matrices analysed. Other 
studies that quantitated morphine and its metabolites in vitreous have reported concentrations 
of morphine and its glucuronides with similar levels than us. Morphine median 0.05mg/L 
(range 0.006-0.195 mg/L); M3G median 0.16 mg/L (range 0.036-0.250 mg/L) and M6G 
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median 0.02 mg/L (0.003-0.046 mg/L) 
19
 Morphine median 0.06mg/L (range 0.011-0.46 
mg/L); M3G median 0.12 mg/L (range 0.016-2.0 mg/L) and M6G median 0.051 mg/L 
(0.014-0.31 mg/L) 
16
 and showing that quantitation of morphine and its metabolites can be 
achieved.  
3.3 Relationships between and femoral blood and the other various matrices 
With the various states that bodies can be found in due to the manner of death or subsequent 
decomposition femoral blood may not be available. In the past it has been suggested that 
other biological samples may be used to predict the femoral blood sample for subsequent 
analysis 
60
. For this reason we investigated the correlation of femoral blood with the various 
matrices.  For free morphine cardiac blood (R
2
 = 0.79), bone marrow (R
2
 = 0.70), muscle (R
2
 
= 0.69) and brain (R
2
 = 0.73) significant correlations were observed, which were not seen 
with liver (R
2
 = 0.49) and vitreous (R
2
 = 0.44). These results in vitreous when compared to 
femoral blood are in agreement with a previous study (R
2 
=  0.26; n=40 
61
, as are the results 
of femoral blood to cardiac blood (R
2 
= 0.76) and psoas muscle (R
2 
= 0.75) 
16
  but don’t agree 
with the results of two other studies that showed significant correlations between femoral 
blood and vitreous concentrations (R
2 
= 0.87; p<0.01, n=69 
62
),  (R
2 
= 0.72; p<0.001, n=52 
60
) 
and (R
2 
= 0.79; p>0.001, n=45 
16
). The differing sets of results obtained by the various groups 
and this study show that although correlations may exist for populations due to differences 
such as individual tolerance, individual metabolism, survival time after the administration of 
the drug and also postmortem redistribution 
63, 64
 that in the absence of a femoral blood 
sample in a case other samples should not be used to attempt to determine the femoral blood 
concentration.  
Due to the complex nature of the data collected the visualisation techniques PCA was applied 
to the data, below in Fig 1 it is shown the 3D scatterplot of morphine results. The figure 
shows the PCA scores from the Morphine levels in different matrices represented by the first 
three PCs. PC1 contains 78.7 % while PC2 contains 8.1% and PC3 contains 5 % of the total 
variance. All matrices from different sites form three groups or classes in the plot: blood, 
bone marrow and brain at the bottom; muscle and liver at the top, vitreous by itself at the 
centre. The plot shows that most biological samples are visually separable when the first 
three PCs are utilised, with cardiac blood and brain showing highest correlation. However, a 
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prediction of result could not be extrapolated since the r square of all possible combination 
was not higher than 0.87 (cardiac blood and brain) (Table 6).    
 
 
3.5.2 Results above 0.3mg/L for cardiac blood 
 
In order to investigate whether our data corresponded to Logan’s work 65 we also analysed 
data for morphine concentration in cardiac blood above and below 0.3mg/L. 
In the PCA plot below (Fig. 2) PC1 contains 73.7 % while PC2 contains 10.6% and PC3 
contains 6.7 % of the total variance. The situation represented in the plot was completely 
different from the previous ones, showing all matrices but vitreous grouped at the bottom of 
the plot, with bone marrow and brain overlaid, all the bloods close to each other, liver and 
muscle beside each other.  
From the Pearson correlation table below brain and cardiac blood showed again to be the two 
matrices with the highest correlation. Cardiac blood and femoral blood r square was 0.7, 
cardiac blood and preserved femoral blood was 0.8 (Table 7).   
 
3.5.3 Results below 0.3mg/L for cardiac blood 
 
For cardiac blood results below 0.3 mg/L the PCA plot and the Pearson table (Fig. 3 and 
Table 7) showed a complete opposite situation compare to the one described by Logan. There 
was not significant correlation between cardiac and femoral blood with r square below 0.57.  
 
3.6 Postmortem redistribution of morphine, morphine-3-glucuronide and morphine-6-
glucuronide 
 
Postmortem redistribution is the change in concentration of a drug (or chemical) at a specific 
anatomical site in the body in the time following death. This can result in the decrease, or 
most commonly increase in the concentration of a drug after death leading to complications 
in the interpretation of postmortem drug concentrations. A ratio of cardiac blood (CB) to 
peripheral (femoral) blood (FB) drug concentration >1 may indicate that a drug undergoes 
postmortem redistribution. The mean CB:FB ratio of morphine in the cases was 1.8 (range 
0.1-11.0) similar to previous studies 1.2 (range 0.05-2.8) 
66
, 2.2 (range 1.0 – 5.8) 67 and 2.2 
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(range 0.2-9.2) 
65
. Our mean CB:FB for M3G 2.7 (range 0.0 – 8.7) and M6G mean 2.6 (range 
0.5 – 8.8) were larger than those previously reported 1.1 and 1.3 respectively 68. Indicating 
that M, M3G and M6G may all undergo postmortem redistribution however this ratio may 
also however just represent anatomical site-to-site differences in drug concentration due to 
incomplete distribution before death 
69
 and more studies may be needed to confirm this.  
3.5 Conclusions 
The results of this study give 44 complete cases with morphine, M3G & M6G concentrations 
in a variety of common samples to aid practitioners in the interpretation of heroin and 
morphine related cases. Due to the possible postmortem redistribution of morphine and its 
metabolites the best sample to use for interpretation of the possible role of morphine in a 
death is femoral blood. Although some other sample morphine concentrations correlate well 
with those of femoral blood (bone marrow, muscle and brain) they should not be used to try 
to estimate the femoral blood concentration, but may be able to aid interpretation when blood 
samples are not available. Analytical determination of the use of heroin rather than morphine 
or codeine require the detection of 6-MAM, this work confirms, along with data from other 
studies that vitreous is the best sample to use, followed by blood and brain. Where blood is 
not available in some cases it may not be possible to determine heroin/morphine use as in 4 
cases in muscle (3 cases in bone marrow) no morphine, morphine-3-glucuronide or 
morphine-6-glucuronide were detected, even though they were detected in other case 
samples. The best sample after blood for the detection of morphine was either the liver or the 
brain. The postmortem concentrations of morphine seen in these, and other postmortem cases 
overlap with seen in previously reported DUID cases. So as with all interpretations of 
postmortem drug concentration they should be carried out with as much case knowledge as 
possible.    
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Fig 1: 3D scatterplot for morphine concentration for all biological matrices analysed 
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Fig 2: 3D scatterplot for mophine concentration with cardiac blood results higher than 0.3 mg/L 
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Fig 3: 3D scatterplot for morphine concentration with cardiac blood results below 0.3 mg/L 
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Table 1: A) Validation Data for Quantitation of Morphine in Various Matrices by Liquid Chromatography-Mass Spectrometry (LC-MS/MS)  
 Plasma Blood Liver Muscle Bone Marrow Brain Vitreous 
 
QC Concentration (mg/L) 
 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
Accuracy (%) 
 
4.4 -0.2 0.8 -3.5 4.9 -8.9 6.6 -5.0 7.4 -14.6 8.6 8.2 12.2 -4.9 
Precision (Within-run) (%CV) 
 
9.5 7.6 2.7 1.9 2.1 1.9 1.3 1.97 3.1 1.6 11.4 3.5 3.58 0.9 
Precision (Between-run) (%CV) 
 
-12.9 14.8 6.1 6.5 8.9 3.1 8.6 11.2 3.7 8.4 8.1 5.1 11.8 3.6 
Ion suppression/Enhancement (%) 
 
-7.9 -11.0 -11.3 -7.7 2.0 -10.4 -8.2 -2.4 -15.3 -12.9 -12.5 5.3 5.0 -6.1 
Recovery (%) 
 
76.3 77.7 65.0 56.4 37.9 47.8 93.1 73.8 88.1 102.6 81.1 79.1 72.2 75.1 
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Table 1 B) Validation Data for Quantitation of morphine-3-glucuronide in Various Matrices by Liquid Chromatography-Mass Spectrometry (LC-
MS/MS) 
 Plasma Blood Liver Muscle Bone Marrow Brain Vitreous 
 
QC Concentration (mg/L) 
 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
Accuracy (%) 
 
1.9 0.6 6.9 7.25 14.1 14.2 -9.0 -2.3 -1.34 -7.7 5.0 6.3 9.51 14.82 
Precision (Within-run) (%CV) 
 
10.1 8.1 10.6 7.1 14.7 1.7 0.3 4.4 2.5 8.1 8.0 5.5 11.54 13.1 
Precision (Between-run) (%CV) 
 
-13.0 -10.6 11.6 9.6 12.2 11.8 7.9 9.7 12.3 11.3 13.7 5.6 9.9 7.5 
Ion suppression/Enhancement (%) 
 
19.3 -1.3 3.4 7.4 2.8 9.8 7.0 3.3 -3.5 -7.6 10.2 19.1 19.4 14.8 
Recovery (%) 
 
62.1 62.0 62.3 66.2 36.5 47.2 105.5 108.1 97.5 94.6 84.2 76.2 67.8 62.8 
 
 This article is protected by copyright. All rights reserved. 
Table 1 C) Validation Data for Quantitation of morphine-6-glucuronide in Various Matrices by Liquid Chromatography-Mass Spectrometry (LC-
MS/MS) 
 Plasma Blood Liver Muscle Bone Marrow Brain Vitreous 
 
QC Concentration (mg/L) 
 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
Accuracy (%) 
 
6.4 6.3 10.2 12.6 12.7 -11.1 14.4 -14.5 3.1 -7.1 9.9 6.7 -9.12 13.5 
Precision (Within-run) (%CV) 
 
8.8 11.4 4.53 5.6 14.3 4.3 3.4 2.9 6.5 5.4 6.4 2.0 4.8 0.2 
Precision (Between-run) (%CV) 
 
-11.9 9.3 11.7 14.4 14.7 12.2 8.6 8.4 14.9 14.7 13.2 9.2 12.6 14.7 
Ion suppression/Enhancement (%) 
 
-9.4 -13.7 -0.5 -3.2 -17.2 -13.7 9.6 19.5 9.8 9.6 13.8 -1.9 -8.4 2.3 
Recovery (%) 
 
75.6 71.2 66.7 44.9 36.5 47.2 81.2 96.7 93.8 97.9 105.4 104.7 60.0 65.3 
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Table 2: Frequency of positive results for each compound (expressed as a percentage) among 
all 44 cases analysed.  
 
 
Morphine M-3-G M-6-G 6-MAM Codeine Noscapine Papaverine 
Cardiac 
Blood 
100 100 86 43 82 84 59 
Fem 
Blood 
100 100 86 52 77 82 50 
Liver 95 98 89 2 55 75 59 
Muscle 86 84 50 32 34 64 41 
Bone 
Marrow 
91 75 41 5 41 70 52 
Brain 98 84 43 43 55 68 55 
Preserved 
Femoral 
Blood 
100 98 82 61 82 84 50 
Preserved 
Vitreous 
100 95 84 100 77 91 39 
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Table 3: Concentrations of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucurionide observed in a variety of 
autopsy samples.  
Case Matrix Morphine M-3-G M-6-G 
1 CB 0.17 0.3 0.1 
 FB 0.1 0.32 0.11 
 L 0.28 0.29 0.15 
 M BLOQ 0.06 BLOQ 
 BM 0.08 0.14 BLOQ 
 Br 0.15 BLOQ BLOQ 
 VH 0.07 0.07 0.02 
2 CB 1.02 0.37 0.09 
 FB 0.37 0.05 0.02 
 L 2.26 1.61 0.61 
 M 0.25 BLOQ 0.05 
 BM 0.97 BLOQ 0.09 
 Br 0.75 BLOQ 0.05 
 VH 0.22 0.04 0.02 
3 CB 0.1 0.29 0.13 
 FB 0.06 0.12 0.04 
 L 0.28 0.22 0.2 
 M 0.07 0.07 0.06 
 BM 0.19 0.1 0.1 
 Br 0.14 0.08 0.06 
 VH 0.04 0.2 0.06 
4 CB 0.53 0.14 0.05 
 FB 0.22 0.03 BLOQ 
 L 0.95 1.68 0.57 
 M 0.36 BLOQ BLOQ 
 BM 0.38 BLOQ BLOQ 
 Br 0.82 BLOQ BLOQ 
 VH 0.06 BLOQ BLOQ 
5 CB 0.41 0.38 0.14 
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 FB 0.25 0.09 0.03 
 L 2.55 2.09 1.76 
 M 0.48 0.08 ND 
 BM 0.5 0.14 0.09 
 Br 0.14 ND ND 
 VH 0.19 0.23 0.07 
6 CB 0.15 0.13 0.04 
 FB 0.07 0.02 BLOQ 
 L 0.48 0.4 0.19 
 M 0.27 ND ND 
 BM 0.21 ND ND 
 Br 0.12 ND ND 
 VH 0.04 0.02 BLOQ 
7 CB 1.85 0.97 0.21 
 FB 1.35 0.64 0.14 
 L 2.21 4.68 1.67 
 M 1.13 0.24 0.15 
 BM 3.23 0.32 0.07 
 Br 1.96 1.12 0.04 
 VH 0.33 0.31 0.07 
8 CB 0.3 0.71 0.15 
 FB 0.21 0.27 0.06 
 L 0.78 1.25 0.46 
 M ND ND ND 
 BM 0.31 0.07 0.06 
 Br 0.24 BLOQ 0.03 
 VH 0.11 0.12 0.04 
Case Matrix Morphine M-3-G M-6-G 
9 CB 0.49 0.89 0.28 
 FB 0.33 0.41 0.13 
 L 1.12 1.04 0.43 
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 M ND 0.2 0.06 
 BM 0.24 0.19 0.06 
 Br 0.27 0.05 BLOQ 
 VH 0.18 0.46 0.1 
10 CB 0.56 0.73 0.17 
 FB 0.57 0.48 0.09 
 L 0.69 0.53 0.19 
 M 0.5 0.11 ND 
 BM 0.59 0.2 ND 
 Br 0.51 0.03 ND 
 VH 0.1 0.12 0.02 
11 CB 0.03 0.06 BLOQ 
 FB 0.13 0.13 0.04 
 L 0.98 2.01 0.11 
 M 0.13 0.23 0.09 
 BM 0.07 0.11 BLOQ 
 Br 0.06 BLOQ ND 
 VH 0.03 0.15 0.03 
12 CB 0.02 0.14 0.03 
 FB 0.03 0.11 0.02 
 L 0.08 0.09 BLOQ 
 M BLOQ BLOQ ND 
 BM BLOQ BLOQ ND 
 Br 0.07 BLOQ ND 
 VH 0.03 0.05 0.02 
13 CB 0.29 0.26 0.06 
 FB 0.08 0.14 0.04 
 L 0.21 0.25 0.15 
 M 0.12 0.13 0.08 
 BM 0.21 0.12 0.07 
 Br 0.21 0.11 0.05 
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 VH 0.15 0.19 0.06 
14 CB 0.2 0.27 0.09 
 FB 0.1 0.05 0.02 
 L 0.44 0.23 0.16 
 M 0.06 BLOQ ND 
 BM 0.05 BLOQ ND 
 Br 0.18 BLOQ ND 
 VH 0.06 0.08 0.02 
15 CB BLOQ 0.01 ND 
 FB BLOQ 0.01 ND 
 L ND ND ND 
 M ND ND ND 
 BM ND ND ND 
 Br ND ND ND 
 VH BLOQ ND ND 
16 CB 0.02 0.06 0.01 
 FB 0.02 0.02 ND 
 L 0.08 BLOQ BLOQ 
 M 0.06 BLOQ ND 
 BM BLOQ BLOQ ND 
 Br 0.07 BLOQ ND 
 VH 0.06 0.05 0.01 
     
     
Case Matrix Morphine M-3-G M-6-G 
17 CB 0.13 0.24 0.07 
 FB 0.14 0.33 0.07 
 L 0.37 0.29 0.21 
 M 0.48 0.11 ND 
 BM ND ND ND 
 Br 0.11 0.04 ND 
 This article is protected by copyright. All rights reserved. 
 VH 0.07 0.09 BLOQ 
18 CB 0.66 0.06 0.05 
 FB 0.16 0.01 0.01 
 L 0.58 0.13 0.18 
 M 0.28 0.07 ND 
 BM 0.23 ND ND 
 Br 0.62 ND ND 
 VH 0.16 0.02 ND 
19 CB 0.26 0.43 0.1 
 FB 0.19 0.17 0.05 
 L 0.7 1.17 0.57 
 M 0.22 BLOQ ND 
 BM ND BLOQ ND 
 Br 0.25 BLOQ ND 
 VH 0.08 0.15 0.01 
20 CB 0.3 0.56 0.11 
 FB 0.33 0.38 0.07 
 L 0.73 0.17 BLOQ 
 M BLOQ 0.07 ND 
 BM BLOQ 0.06 ND 
 Br 0.27 0.05 BLOQ 
 VH 0.15 0.25 0.06 
21 CB 0.02 0.02 ND 
 FB 0.02 0.02 ND 
 L 0.08 0.1 ND 
 M BLOQ BLOQ ND 
 BM BLOQ BLOQ ND 
 Br BLOQ BLOQ ND 
 VH 0.02 0.02 ND 
22 CB 0.11 0.04 ND 
 FB 0.01 0.02 ND 
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 L 0.19 0.18 0.13 
 M 0.14 BLOQ ND 
 BM 0.12 BLOQ ND 
 Br 0.08 BLOQ ND 
 VH 0.02 BLOQ ND 
23 CB 0.04 0.08 ND 
 FB 0.03 0.08 ND 
 L 0.13 0.08 ND 
 M 0.01 ND ND 
 BM 0.1 ND ND 
 Br 0.04 ND ND 
 VH 0.02 0.06 ND 
24 CB BLOQ 0.09 ND 
 FB BLOQ 0.02 ND 
 L 0.05 0.09 ND 
 M ND ND ND 
 BM 0.01 ND ND 
 Br 0.01 ND ND 
 VH BLOQ ND ND 
     
     
Case Matrix Morphine M-3-G M-6-G 
25 CB 0.78 1.14 0.48 
 FB 0.78 1.12 0.66 
 L 1.34 1.85 0.83 
 M 0.64 0.23 0.09 
 BM 0.49 0.04 ND 
 Br 0.46 0.04 ND 
 VH 0.27 0.32 0.07 
26 CB 0.33 0.24 0.12 
 FB 0.14 0.03 0.02 
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 L 0.33 0.39 0.28 
 M 0.09 ND ND 
 BM 0.25 ND ND 
 Br 0.36 ND ND 
 VH 0.05 0.03 0.02 
27 CB 0.01 0.03 ND 
 FB 0.02 0.04 0.01 
 L ND BLOQ ND 
 M ND BLOQ ND 
 BM 0.12 0.01 ND 
 Br 0.04 BLOQ ND 
 VH 0.02 0.02 ND 
28 CB 0.09 0.19 0.04 
 FB 0.1 0.53 0.08 
 L 0.47 0.24 0.09 
 M 0.11 0.25 0.08 
 BM 0.11 0.17 ND 
 Br 0.28 0.08 ND 
 VH 0.12 0.65 0.08 
29 CB 0.35 0.79 0.16 
 FB 0.21 0.33 0.05 
 L 0.67 0.59 0.36 
 M 0.19 0.07 ND 
 BM 0.49 0.07 ND 
 Br 0.21 0.05 ND 
 VH 0.08 0.18 0.03 
30 CB 0.49 1.74 0.21 
 FB 0.51 0.99 0.12 
 L 1.19 1.7 0.24 
 M 0.89 0.91 BLOQ 
 BM 0.3 0.13 BLOQ 
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 Br 0.5 BLOQ BLOQ 
 VH 0.19 0.33 0.03 
31 CB 0.59 1.74 0.35 
 FB 0.19 0.27 0.04 
 L 0.88 0.61 0.36 
 M 0.28 0.14 BLOQ 
 BM 0.07 BLOQ ND 
 Br 0.17 0.04 BLOQ 
 VH 0.1 0.24 0.03 
32 CB 0.29 0.57 0.09 
 FB 0.24 0.45 0.04 
 L 0.77 1.12 0.6 
 M 0.21 0.07 BLOQ 
 BM BLOQ BLOQ BLOQ 
 Br 0.2 0.4 BLOQ 
 VH 0.2 0.57 0.03 
     
     
Case Matrix Morphine M-3-G M-6-G 
33 CB 0.3 0.13 0.02 
 FB 0.3 0.16 0.02 
 L 0.77 0.94 0.54 
 M BLOQ BLOQ ND 
 BM 0.49 BLOQ BLOQ 
 Br 0.28 BLOQ ND 
 VH 0.49 0.2 0.02 
34 CB 0.85 0.9 0.29 
 FB 0.39 0.17 0.06 
 L 1.46 1.19 0.49 
 M 0.31 0.14 BLOQ 
 BM 0.05 BLOQ ND 
 This article is protected by copyright. All rights reserved. 
 Br 0.71 0.07 BLOQ 
 VH 0.33 0.62 0.19 
35 CB 0.01 0.02 BLOQ 
 FB 0.16 0.89 0.16 
 L 0.1 BLOQ BLOQ 
 M BLOQ BLOQ BLOQ 
 BM BLOQ BLOQ BLOQ 
 Br BLOQ BLOQ BLOQ 
 VH 0.03 0.02 0.01 
36 CB 0.12 0.17 0.03 
 FB 0.09 0.2 0.04 
 L 0.2 0.17 0.09 
 M 0.07 0.07 BLOQ 
 BM BLOQ ND ND 
 Br 0.12 BLOQ BLOQ 
 VH 0.11 0.1 0.02 
37 CB 0.08 0.27 0.03 
 FB 0.1 0.48 0.03 
 L 0.25 0.14 0.07 
 M BLOQ BLOQ BLOQ 
 BM BLOQ ND ND 
 Br 0.09 0.04 BLOQ 
 VH 0.1 0.14 0.02 
38 CB BLOQ 0.02 BLOQ 
 FB BLOQ 0.01 BLOQ 
 L BLOQ BLOQ BLOQ 
 M ND ND ND 
 BM ND ND ND 
 Br BLOQ BLOQ ND 
 VH 0.01 0.03 BLOQ 
39 CB 0.22 0.2 0.04 
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 FB 0.15 0.06 0.01 
 L 0.44 0.79 0.24 
 M 0.2 BLOQ ND 
 BM BLOQ ND ND 
 Br 0.06 BLOQ ND 
 VH 0.07 0.04 BLOQ 
40 CB 0.19 0.71 0.13 
 FB 0.17 0.4 0.06 
 L 0.41 0.46 0.25 
 M 0.13 0.13 BLOQ 
 BM BLOQ BLOQ ND 
 Br 0.2 0.07 BLOQ 
 VH 0.08 0.31 0.04 
     
     
Case Matrix Morphine M-3-G M-6-G 
41 CB 0.07 0.12 0.02 
 FB 0.05 0.14 0.02 
 L 0.14 0.11 0.05 
 M BLOQ BLOQ BLOQ 
 BM BLOQ BLOQ BLOQ 
 Br 0.05 BLOQ BLOQ 
 VH 0.04 0.1 0.01 
42 CB 0.35 0.26 0.06 
 FB 0.19 0.03 BLOQ 
 L 0.9 0.81 0.23 
 M 0.09 BLOQ BLOQ 
 BM 0.3 BLOQ BLOQ 
 Br 0.21 BLOQ ND 
 VH 0.07 0.02 BLOQ 
43 CB 0.01 0.12 0.01 
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 FB BLOQ 0.05 BLOQ 
 L BLOQ BLOQ BLOQ 
 M BLOQ BLOQ BLOQ 
 BM BLOQ BLOQ BLOQ 
 Br BLOQ BLOQ BLOQ 
 VH 0.03 0.05 BLOQ 
44 CB 0.27 0.03 BLOQ 
 FB 0.13 BLOQ BLOQ 
 L 0.56 0.84 0.29 
 M 0.13 BLOQ BLOQ 
 BM 0.22 BLOQ BLOQ 
 Br 0.27 BLOQ ND 
 VH 0.13 0.07 BLOQ 
Abbreviations: CB – Cardiac Blood, FB – Femoral Blood,             L – Liver, M – Muscle (Psoas), BM – Bone Marrow,                    
Br – Brain (Thalamus), VH – Vitreous Humour, ND- Not Detected,                 BLOQ – Detected Below Limit of Quantitation,                               
M-3-G – Morphine-3-Glucuronide, M-6-G – Morphine-6-Glucuronide 
Concentrations: Fluids – mg/L Solids – mg/kg 
 
  
 This article is protected by copyright. All rights reserved. 
Table 4: Morphine, Mophine-3-glucuronide and Mophine-6-glucuronide range, mean and median from all cases 
analysed.  
 
Analyte  
Morphine 
Cardiac 
Blood 
(mg/L) 
Fem Blood 
(mg/L) 
Liver 
(mg/kg) 
Muscle 
(mg/kg) 
Bone M 
(mg/kg) 
Brain 
(mg/kg) 
F/O 
Fem 
Blood 
(mg/L) 
Vitreous 
(mg/L) 
Range 
0.01-
1.85 
0.01-1.35 
0.01-
2.55 
0.01-1.13 
0.01-
3.23 
0.01-1.96 
0.01-
1.19 
0.01-0.49 
Mean 0.30 0.20 0.65 0.21 0.26 0.26 0.18 0.11 
Median 0.21 0.14 0.48 0.13 0.12 0.18 0.14 0.08 
M3G         
Range 
0.01-
1.74 
0.01-1.12 
0.01-
4.68 
0.01-0.91 
0.01-
0.32 
0.01-1.12 
0.01-
0.88 
0.01-0.65 
Mean 0.38 0.23 0.71 0.09 0.06 0.07 0.20 0.16 
Median 0.24 0.14 0.39 0.07 0.01 0.01 0.13 0.10 
M6G         
Range 
0.01-
0.48 
0.01-0.66 
0.01-
1.76 
0.01-0.15 
0.01-
0.1 
0.01-0.06 
0.01-
0.46 
0.01-0.19 
Mean 0.10 0.06 0.33 0.03 0.03 0.02 0.06 0.03 
Median 0.08 0.04 0.21 0.01 0.01 0.01 0.04 0.02 
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Table 5: Blood concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide in postmortem (PM) and driving under the influence of drugs (DUID) 
cases. 
Reference Case Type Sample Number of cases [Morphine] mg/L [M3G] mg/L [M6G] mg/L 
        Median Range Median Range Median Range 
This Study PM Femoral 44 0.14 0.01 - 1.19 0.14 0.01 - 1.12 0.04 0.01 - 0.66 
16 PM Femoral 45 0.22 0.01 – 1.1 0.25 0.0036 – 2.4 0.052 0.015 – 0.58  
18 PM Femoral ? 0.11 0.01 - 0.57     
 
  
50 PM Femoral 8 0.26 0 – 0.8 0.36 0 - 1.04 0.1 0 - 0.29 
70 PM Femoral 126 0.22 0.01 – 3.55     
 
  
71 PM Femoral 28 0.16 0.02 – 3.30     
 
  
68 PM Femoral 40 0.25 0.06 – 0.80 0.43 0.13 - 2.22 0.09 0.02 - 0.5 
65 PM Femoral 32 0.08 0.007 – 1.61     
 
  
6 PM Femoral 766 0.24 0.04 – 5.5     
 
  
6 DUID Blood 124 0.15 0.02 - 1.13         
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Table 6: r
2
 values describing correlation for data where zero was included. 
 Cardiac 
Blood 
Femoral 
Blood 
Liver Muscle 
Bone 
Marrow 
Brain 
Preserved 
Femoral Blood 
Femoral Blood 0.793       
Liver 0.632 0.511      
Muscle 0.573 0.683 0.435     
Bone Marrow 0.698 0.703 0.389 0.476    
Brain 0.872 0.737 0.440 0.553 0.765   
Preserved 
Femoral Blood 
0.844 0.917 0.485 0.579 0.739 0.788  
Preserved 
Vitreous 
0.448 0.446 0.427 0.219 0.244 0.344 0.419 
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Table  7: r2 values describing correlation for data with cardiac blood results higher and lower than 0.3 
mg/L 
  
Cardiac Blood Fem Blood Liver Muscle Bone Marrow Brain F/O Fem Blood 
correlation for data with cardiac blood results higher than 0.3 mg/L 
Fem Blood         0.706       
Liver 0.489 0.330      
Muscle 0.560 0.716 0.384     
Bone Marrow 0.728 0.712 0.335 0.490    
Brain 0.860 0.660 0.292 0.520 0.766   
F/O Fem Blood 0.805 0.918 0.324 0.632 0.785 0.760  
Vitreous 0.202 0.230 0.217 0.080 0.144 0.139 0.194 
correlation for data with cardiac blood results lower than 0.3 mg/L 
Fem Blood 0.571       
Liver 0.473 0.595      
Muscle 0.311 0.320 0.332     
Bone Marrow 0.049 0.003 0.042 0.004    
Brain 0.622 0.399 0.426 0.167 0.125   
F/O  
Fem Blood 
0.438 0.541 0.257 0.095 0.003 0.265  
Vitreous 0.552 0.540 0.342 0.152 0.008 0.571 0.518 
 
